Résultats des essais cliniques 2243 sur 3 ans et CONTROL II avec efalizumab

Psoriasis is a chronic disease frequently requiring extended treatment. Today there are data on patients treated with efalizumab during 36 months for psoriasis as well as new data on the specific locations of psoriasis that were excluded from the first studies with biotherapies. These studies demonstrated that efalizumab can provide extended significant improvement of psoriasis, including in areas that are usually difficult to treat (nails, scalp, and palmoplantar psoriasis). The risk of relapse after treatment was 11 % in patients who responded to treatment and the risk of worsening in nonresponders was 9 %. No new undesirable effect was demonstrated in these studies, in particular in terms of malignant diseases, infections, and notably opportunistic infections.